Early therapy evaluation of combined anti-death receptor 5 antibody and gemcitabine in orthotopic pancreatic tumor xenograftsby diffusion-weighted magnetic resonance imaging

Cancer Research

Volumn 68, Issue 20, 2008, Pages 8369-8376

  Kim, Hyunki ^a,b,g   Morgan, Desiree E ^a,g   Buchsbaum, Donald J ^c,g   Zeng, Huadong ^d,g   Grizzle, William E ^e   Warram, Jason M ^e   Stockard, Cecil R ^g   McNally, Lacey R ^a,c   Long, Joshua W ^f   Sellers, Jeffrey C ^c   Forero, Andres ^d,g   Zinn, Kurt R ^a,d,e,g  

^a University of Alabama   (United States)

^b 803 Shelby Interdisciplinary Biomedical Research Building   (United States)

^c University of Alabama at Birmingham   (United States)

^d and Clinical Center   (United States)

^e University of Alabama at Birmingham   (United States)

^f University of Alabama at Birmingham   (United States)

^g UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; GEMCITABINE; SODIUM CHLORIDE; TRA 8; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIOLUMINESCENCE; CANCER SURVIVAL; COMBINED IMMUNODEFICIENCY; CONTROLLED STUDY; DIFFUSION WEIGHTED IMAGING; DRUG EFFICACY; HUMAN; HUMAN CELL; MOUSE; MULTIPLE CYCLE TREATMENT; NICK END LABELING; NONHUMAN; PANCREAS TUMOR; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR REGRESSION; TUMOR VOLUME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; DEOXYCYTIDINE; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; HUMANS; MICE; PANCREATIC NEOPLASMS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 54249116378     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-1771     Document Type: Article

References (38)

1. Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13.
2. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB III. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002;20:3270-5.
3. Rocha Lima CM, Green MR, Rotche R, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 2004;22:3776-83.
4. Di Costanzo F, Carlini P, Doni L, et al. Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC). Br J Cancer 2005;93:185-9.
5. Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005;23:3509-16.
6. Ibrahim SM, Ringel J, Schmidt C, et al. Pancreatic adenocarcinoma cell lines show variable susceptibility to TRAIL-mediated cell death. Pancreas 2001;23:72-9.
7. Ozawa F, Friess H, Kleeff J, et al. Effects and expression of TRAIL and its apoptosis-promoting receptors in human pancreatic cancer. Cancer Lett 2001;163:71-81.
8. Sheridan JP, Marsters SA, Pitti RM, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997;277:818-21.
9. Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999;5:157-63.
10. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999;104:155-62.
11. Chinnaiyan AM, Prasad U, Shankar S, et al. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc Natl Acad Sci U S A 2000;97:1754-9.
12. Pan G, O'Rourke K, Chinnaiyan AM, et al. The receptor for the cytotoxic ligand TRAIL. Science 1997;276:111-3.
13. Walczak H, Degli-Esposti MA, Johnson RS, et al. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J 1997;16:5386-97.
14. Chaudhary PM, Eby M, Jasmin A, Bookwalter A, Murray J, Hood L. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-κB pathway. Immunity 1997;7:821-30.
15. Schneider P, Thome M, Burns K, et al. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-κB. Immunity 1997;7:831-6.
16. Jo M, Kim TH, Seol DW, et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 2000;6:564-7.
17. Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997;277:815-8.
18. Degli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA, Goodwin RG. The novel receptor TRAIL-R4 induces NF-κB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 1997;7:813-20.
19. Degli-Esposti MA, Smolak PJ, Walczak H, et al. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med 1997;186:1165-70.
20. Emery JG, McDonnell P, Burke MB, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998;273:14363-7.
21. Ichikawa K, Liu W, Zhao L, et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 2001;7:954-60.
22. Derosier LC, Vickers SM, Zinn KR, et al. TRA-8 anti-DR5 monoclonal antibody and gemcitabine induce apoptosis and inhibit radiologically validated orthotopic pancreatic tumor growth. Mol Cancer Ther 2007;6:3198-207.
23. Saleh A, Srinivasula SM, Acharya S, Fishel R, Alnemri ES. Cytochrome c and dATP-mediated oligomerization of Apaf-1 is a prerequisite for procaspase-9 activation. J Biol Chem 1999;274:17941-5.
24. Li P, Nijhawan D, Budihardjo I, et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997;91:479-89.
25. Moffat BA, Chenevert TL, Meyer CR, et al. The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome. Neoplasia 2006;8:259-67.
26. Galons JP, Altbach MI, Paine-Murrieta GD, Taylor CW, Gillies RJ. Early increases in breast tumor xenograft water mobility in response to paclitaxel therapy detected by non-invasive diffusion magnetic resonance imaging. Neoplasia 1999;1:113-7.
27. Koh DM, Scurr E, Collins D, et al. Predicting response of colorectal hepatic metastasis: value of pretreatment apparent diffusion coefficients. AJR Am J Roentgenol 2007;188:1001-8.
28. Chenevert TL, Stegman LD, Taylor JM, et al. Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst 2000;92:2029-36.
29. Abrams MJ, Juweid M, tenKate CI, et al. Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats. J Nucl Med 1990;31:2022-8.
30. 99mTc]Tricine: a useful precursor complex for the radiolabeling of hydrazinonicotinate protein conjugates. Bioconjug Chem 1995;6:635-8.
31. Lowry O, Rosebrough N, Farr L, Randall R. Protein measurement with the folin phenol reagent. J Biol Chem 1951;193:265-75.
32. Sack I, Gedat E, Bernarding J, Buntkowsky G, Braun J. Magnetic resonance elastography and diffusion-weighted imaging of the sol/gel phase transition in agarose. J Magn Reson 2004;166:252-61.
33. Pezold JC, Zinn K, Talbert MA, Desmond R, Rosenthal EL. Validation of ultrasonography to evaluate murine orthotopic oral cavity tumors. ORL J Otorhinolaryngol Relat Spec 2006;68:159-63.
34. Sternberg SR. Biomedical image processing. IEEE Comput 1983;16:22-34.
35. Neter J, Kutner MH, Nachtsheim JC, Wasserman W. Applied linear statistical models. 4th ed. Columbus: The McGraw-Hill Companies, Inc.; 1996.
36. Derosier LC, Buchsbaum DJ, Oliver PG, et al. Combination treatment with TRA-8 anti death receptor 5 antibody and CPT-11 induces tumor regression in an orthotopic model of pancreatic cancer. Clin Cancer Res 2007;13:5535-43s.
37. Kim H, Chaudhuri TR, Buchsbaum DJ, Wang D, Zinn KR. Single-photon emission computed tomography imaging with a humanized, apoptosis-inducing antibody targeting human death receptor 5 in pancreas and breast tumor xenografts. Cancer Biol Ther 2007;6:1396-402.
38. Kim H, Chaudhuri TR, Buchsbaum DJ, Wang D, Zinn KR. High-resolution single-photon emission computed tomography and X-ray computed tomography imaging of Tc-99m-labeled anti-DR5 antibody in breast tumor xenografts. Mol Cancer Ther 2007;6:866-75.